Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Recruiting now

Conditions studied: Metastatic Castration Resistant Prostate Cancer

In brief

This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.

Key facts

Study ID
NCT07093801
Run by
Novartis Pharmaceuticals
People needed
300
Starts
2025-07-30
Expected to finish
2029-03-30
Last updated by the study team
2026-05-15

Who can join

Age: 18 and older, up to 99. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.